Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00548249 · ClinicalTrials.gov registry record · Phase 2
Dose Ranging Study of Dialysate Containing Soluble Iron to Treat Subjects With End Stage Renal Disease (ESRD) Receiving Chronic Hemodialysis
A Phase 2 study, sponsored by Rockwell Medical Technologies.
- Completed
- Registry status
- Phase 2
- Development phase
- 131
- Enrollment target
NCT00548249 is a Phase 2 study that has completed, run by Rockwell Medical Technologies. The registered enrollment target is 131 participants.
The verdict
NCT00548249, a Phase 2 study, has completed, sponsored by Rockwell Medical Technologies.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 131 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Dialysate containing soluble iron (Soluble Ferric Pyrophosphate) is safe and effective in maintaining physiological iron levels during chronic hemodialysis.
Interventions
- DEVICE Standard Bicarbonate Solution
- DRUG Soluble Ferric Pyrophosphate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2007-08 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00548249
The ClinicalTrials.gov registry entry for NCT00548249 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rockwell Medical Technologies, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard Bicarbonate Solution is the first listed.
NCT00548249 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00548249 about?
NCT00548249 is a clinical study titled "Dose Ranging Study of Dialysate Containing Soluble Iron to Treat Subjects With End Stage Renal Disease (ESRD) Receiving Chronic Hemodialysis". The purpose of this study is to determine whether Dialysate containing soluble iron (Soluble Ferric Pyrophosphate) is safe and effective in maintaining physiological iron levels during chronic hemodialysis.
What is the current status of trial NCT00548249?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 131 participants. The study started on 2007-08. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00548249?
The interventions under investigation include: Standard Bicarbonate Solution (DEVICE), Soluble Ferric Pyrophosphate (DRUG).
Who is sponsoring clinical trial NCT00548249?
This trial is sponsored by Rockwell Medical Technologies, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.